Recall of Infant Cold Medicines
October 18, 2007
Pfizer announced today that it will no longer market inhaled insulin treatment Exubera. "Despite our best efforts, Exubera has failed to gain the acceptance of patients and physicians," Pfizer CEO Jeff Kindler said in a statement. "We have therefore concluded that further investment in this product is unwarranted."
Pfizer "will work with physicians to transition Exubera patients to other treatment options in the next three months," Kindler said. "We remain committed to investing significant resources in the development of new and innovative medicines to manage diabetes, including monitoring inhalation technologies and other innovative delivery systems for insulin and other medicines."
Pfizer will hold a conference call later today to discuss its third quarter results.